Rocket Pharmaceuticals, Inc.
General ticker "RCKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $384.4M (TTM average)
Rocket Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 13.4%.
Estimated limits based on current volatility of 3.3%: low 3.37$, high 3.60$
Factors to consider:
- Total employees count: 202 (-32.4%) as of 2025
- Top business risk factors: Capital shortage, Clinical trial failure, Regulatory and compliance, Manufacturing scale up, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.94$, 5.80$]
- 2026-12-31 to 2027-12-31 estimated range: [2.18$, 6.15$]
Financial Metrics affecting the RCKT estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0.50 <= 0.74
- Positive: Investing cash flow per share per price, % of 27.38 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
Short-term RCKT quotes
Long-term RCKT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $259.66MM | $273.20MM | $231.75MM |
| Operating Income | $-259.66MM | $-273.20MM | $-231.75MM |
| Non-Operating Income | $14.06MM | $14.46MM | $8.62MM |
| Interest Expense | $1.88MM | $1.89MM | $1.89MM |
| R&D Expense | $186.34MM | $171.24MM | $142.01MM |
| Income(Loss) | $-245.59MM | $-258.75MM | $-223.12MM |
| Net Income(Loss)* | $-245.59MM | $-258.75MM | $-223.12MM |
| Stockholders Equity | $492.57MM | $463.23MM | $277.22MM |
| Assets | $566.34MM | $527.70MM | $330.45MM |
| Operating Cash Flow | $-194.92MM | $-209.72MM | $-190.01MM |
| Capital expenditure | $16.47MM | $5.86MM | $0.44MM |
| Investing Cash Flow | $-98.07MM | $131.71MM | $103.77MM |
| Financing Cash Flow | $208.40MM | $185.74MM | $0.15MM |
| Earnings Per Share** | $-2.92 | $-2.73 | $-2.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.